|
|
|
|
||
Re: Takeovers and rights selling in biolandI still believe that Insmed is a target for acquisition and that the suitor is waiting for a few developments before closing a deal. EU approval, front line therapy and Japanese filing announcements could seal this deal. And for a lot more than most of us expect. |
return to message board, top of board |